PortalPublikationenCarfilzomib-dexamethasone versus subcutaneous or intravenous...

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

Standard

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. / Goldschmidt, Hartmut; Moreau, Philippe; Ludwig, Heinz; Niesvizky, Ruben; Chng, Wee-Joo; Joshua, Douglas; Weisel, Katja; Spencer, Andrew; Orlowski, Robert Z; Feng, Shibao; Iskander, Karim S; Dimopoulos, Meletios A.

in: LEUKEMIA LYMPHOMA, Jahrgang 59, Nr. 6, 06.2018, S. 1364-1374.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Goldschmidt, H, Moreau, P, Ludwig, H, Niesvizky, R, Chng, W-J, Joshua, D, Weisel, K, Spencer, A, Orlowski, RZ, Feng, S, Iskander, KS & Dimopoulos, MA 2018, 'Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study', LEUKEMIA LYMPHOMA, Jg. 59, Nr. 6, S. 1364-1374. https://doi.org/10.1080/10428194.2017.1376743

APA

Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W-J., Joshua, D., Weisel, K., Spencer, A., Orlowski, R. Z., Feng, S., Iskander, K. S., & Dimopoulos, M. A. (2018). Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. LEUKEMIA LYMPHOMA, 59(6), 1364-1374. https://doi.org/10.1080/10428194.2017.1376743

Vancouver

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W-J, Joshua D et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. LEUKEMIA LYMPHOMA. 2018 Jun;59(6):1364-1374. https://doi.org/10.1080/10428194.2017.1376743

Bibtex

@article{a531946a566f4955953c32610b656885,
title = "Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study",
abstract = "This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Retreatment, Treatment Outcome, Clinical Trial, Phase III, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Hartmut Goldschmidt and Philippe Moreau and Heinz Ludwig and Ruben Niesvizky and Wee-Joo Chng and Douglas Joshua and Katja Weisel and Andrew Spencer and Orlowski, {Robert Z} and Shibao Feng and Iskander, {Karim S} and Dimopoulos, {Meletios A}",
year = "2018",
month = jun,
doi = "10.1080/10428194.2017.1376743",
language = "English",
volume = "59",
pages = "1364--1374",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "6",

}

RIS

TY - JOUR

T1 - Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

AU - Goldschmidt, Hartmut

AU - Moreau, Philippe

AU - Ludwig, Heinz

AU - Niesvizky, Ruben

AU - Chng, Wee-Joo

AU - Joshua, Douglas

AU - Weisel, Katja

AU - Spencer, Andrew

AU - Orlowski, Robert Z

AU - Feng, Shibao

AU - Iskander, Karim S

AU - Dimopoulos, Meletios A

PY - 2018/6

Y1 - 2018/6

N2 - This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.

AB - This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Dexamethasone

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Oligopeptides

KW - Recurrence

KW - Retreatment

KW - Treatment Outcome

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1080/10428194.2017.1376743

DO - 10.1080/10428194.2017.1376743

M3 - SCORING: Journal article

C2 - 28937327

VL - 59

SP - 1364

EP - 1374

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 6

ER -